Viridian Therapeutics, Inc.\DE VRDN
NASDAQ VRDN
$22.92 -0.04 (-0.17%)
As of: Sep 4, 2026 · 3:59 PM EDT

Viridian Therapeutics, Inc.\DE (VRDN) Amortizatization of Intangibles (2016 - 2026)

Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Amortizatization of Intangibles of $1.9 million for Q1 2026, down 19.96% year-over-year from $2.3 million in Q1 2025, and up 5.93% quarter-over-quarter from $1.8 million in Q4 2025.

Analysis

Viridian Therapeutics, Inc.\DE (VRDN) Amortizatization of Intangibles (2016 - 2026) Analysis & Trends

Viridian Therapeutics, Inc.\DE's Amortizatization of Intangibles history runs 11 years deep, the most recent figure standing at $1.9 million for Q1 2026.

  • In Q1 2026, Amortizatization of Intangibles fell 19.96% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $6.3 million (down 52.71% YoY), while the FY2025 annual figure was $6.8 million, down 56.83% from the prior year.
  • Amortizatization of Intangibles for Q1 2026 stood at $1.9 million, up from $1.8 million in the prior quarter.
  • The five-year high for Amortizatization of Intangibles was $4.7 million in Q1 2024, with the low at -$274000.0 in Q1 2022.
  • The 5-year median for Amortizatization of Intangibles is $2.3 million (2025), against an average of $2.1 million.
  • The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles surged 1415.54% in 2023, then sank 66.45% in 2025.
  • Viridian Therapeutics, Inc.\DE's Amortizatization of Intangibles stood at $937000.0 in 2022, then soared by 227.32% to $3.1 million in 2023, then climbed by 4.56% to $3.2 million in 2024, then plunged by 45.34% to $1.8 million in 2025, then gained by 5.93% to $1.9 million in 2026.
  • Business Quant data shows VRDN's Amortizatization of Intangibles at $1.9 million in Q1 2026, $1.8 million in Q4 2025, and $1.1 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.33 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 678,000.00
10 Viridian Therapeutics, Inc.\DE 2.42 Bn 2.42 Bn - 1.45 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.45 Mn
Mar 31, 2026 1.86 Mn
Dec 31, 2025 1.75 Mn
Sep 30, 2025 1.13 Mn
Jun 30, 2025 1.55 Mn
Mar 31, 2025 2.32 Mn
Dec 31, 2024 3.21 Mn
Sep 30, 2024 3.38 Mn
Jun 30, 2024 4.41 Mn
Mar 31, 2024 4.66 Mn
Dec 31, 2023 3.07 Mn
Sep 30, 2023 2.54 Mn
Jun 30, 2023 2.91 Mn
Mar 31, 2023 2.98 Mn
Dec 31, 2022 937,000.00
Sep 30, 2022 -193,000.00
Jun 30, 2022 -260,000.00
Mar 31, 2022 -274,000.00
Dec 31, 2021 -250,000.00
Sep 30, 2021 -234,000.00